William H. Carson Acquires 3,200 Shares of Annexon, Inc. (NASDAQ:ANNX) Stock

Annexon, Inc. (NASDAQ:ANNX) Director William H. Carson bought 3,200 shares of the firm’s stock in a transaction that occurred on Monday, July 1st. The shares were acquired at an average cost of $5.00 per share, for a total transaction of $16,000.00. Following the completion of the acquisition, the director now directly owns 12,800 shares in the company, valued at approximately $64,000. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Annexon Price Performance

Shares of NASDAQ ANNX opened at $4.80 on Thursday. The stock’s fifty day moving average price is $5.00 and its two-hundred day moving average price is $5.08. Annexon, Inc. has a one year low of $1.57 and a one year high of $8.40. The firm has a market cap of $443.11 million, a price-to-earnings ratio of -3.26 and a beta of 1.29.

Annexon (NASDAQ:ANNX) last issued its quarterly earnings data on Monday, May 13th. The company reported ($0.21) EPS for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.11. On average, equities analysts anticipate that Annexon, Inc. will post -0.98 earnings per share for the current fiscal year.

Analyst Ratings Changes

ANNX has been the topic of a number of recent analyst reports. Bank of America boosted their target price on Annexon from $7.00 to $10.00 and gave the stock a “buy” rating in a report on Thursday, March 28th. HC Wainwright reissued a “buy” rating and set a $30.00 target price on shares of Annexon in a report on Tuesday, June 4th. Cantor Fitzgerald reissued an “overweight” rating on shares of Annexon in a report on Wednesday, June 5th. JPMorgan Chase & Co. boosted their target price on Annexon from $11.00 to $13.00 and gave the stock an “overweight” rating in a report on Monday, April 1st. Finally, Wells Fargo & Company decreased their target price on Annexon from $12.00 to $10.00 and set an “overweight” rating on the stock in a report on Wednesday, May 15th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, Annexon currently has a consensus rating of “Buy” and a consensus price target of $15.33.

Institutional Trading of Annexon

Several large investors have recently modified their holdings of ANNX. Ameritas Investment Partners Inc. grew its holdings in shares of Annexon by 78.2% during the 1st quarter. Ameritas Investment Partners Inc. now owns 6,718 shares of the company’s stock worth $48,000 after purchasing an additional 2,949 shares in the last quarter. Tower Research Capital LLC TRC grew its holdings in shares of Annexon by 53.2% during the 4th quarter. Tower Research Capital LLC TRC now owns 11,924 shares of the company’s stock worth $54,000 after purchasing an additional 4,141 shares in the last quarter. Comerica Bank acquired a new stake in shares of Annexon during the 1st quarter worth $72,000. ProShare Advisors LLC acquired a new stake in shares of Annexon during the 1st quarter worth $87,000. Finally, EntryPoint Capital LLC acquired a new stake in shares of Annexon during the 1st quarter worth $98,000.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.